Automation of multi-analyte prostate cancer biomarker immunoassay panel from whole blood by minimum-instrumentation rotational flow control
Point of care
Instrumentation
Multiplex
Fluidics
DOI:
10.1016/j.snb.2018.02.015
Publication Date:
2018-02-19T12:28:09Z
AUTHORS (8)
ABSTRACT
Abstract Early diagnosis and prognosis of prostate cancer (PCa) is increasingly moving towards evaluations based on a strategic combination of biomarkers. The ability to parallelize multi-parameter detection on the same device is hence considered as a substantial improvement compared to conventional, single-marker methods such as total prostate-specific antigen (t-PSA). We demonstrate full rotational control of a centrifugal microfluidic system which is geared to automate multi-step/multi-reagent protocols underlying PCa detection based on a multi-marker panel on a widely autonomous, cost-efficient and rugged point-of-care instrument. Such comprehensive fluidic integration is enabled by a novel type of dissolvable-film (DF) valve which significantly enhances the definition of its critical release frequency by a factor of more than 3 (average spread of ±1.8 Hz), and thus substantially enhances process reliability and integration density on our “Lab-on-a-Disc” (LoaD) platform. This siphon-based centrifugo-pneumatic flow control scheme can be attuned merely by temporal modulation of the spin rate to parallelize three assay protocols in a sample-to-answer fashion; in addition, we demonstrate flexibility of application without redesigning of the cartridge towards variants of the common Enzyme-Linked Immuno-Sorbent Assay (ELISA) format. As a pilot application, we further implement liquid handling automation for the detection of two distinct PCa markers, free PSA and human epidermal growth factor receptor-type 2, (HER2), using two types of ELISA i.e. sandwich and competitive, respectively.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (24)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....